ROLE OF SYSTEMIC OMALIZUMAB IN MANAGEMENT OF ALLERGIC FUNGAL RHINOSINUSITIS

奥马佐单抗 慢性鼻-鼻窦炎 医学 皮肤病科 免疫学 免疫球蛋白E 抗体
作者
Badr Eldin Mostafa,Mohammed Hassan,Tarek Abdel Hamid Hamdi,Anas Mohamed Ali Nasr Askoura,Michael Mounir
出处
期刊:Ain Shams medical journal [TechKnowledge General Trading]
卷期号:70 (4): 371-378 被引量:2
标识
DOI:10.21608/asmj.2019.111340
摘要

Background: Allergic fungal rhinosinusitis (AFRS) is due to the continuous exposure of fungal antigens to an atopic individual. It is caused by type I, IgE mediated (and possibly type III) hypersensitivity reaction to an extramucosal fungal antigen. Medical treatment following the surgery is the standard protocol of management. Steroids (systemic/topical) have been considered as the standard medical treatment for control of the disease despite high recurrence rate and their serious side effects. Instead, omalizumab, a humanized monoclonal anti-IgE antibody, can be tried as a new treatmentmodality with less side effects to control symptoms and decrease the recurrence rate in AFRS patients. It acts by aborting the immunological reaction to sinonasal fungi through preventing the release of inflammatory mediators that cause allergic signs and symptoms. Aim: To evaluate the role of omalizumab for postoperative management of AFRS patients in comparison to topical steroids as regarding symptom free interval and side effects. Patients and methods: A total of 20 patients with AFRS were included in the study. Patients were divided randomly into two equal groups: group A used local steroid and group B used single dose of subcutaneous omalizumab. Clinical parameters were compared at 4,8,12 and 24 weeks. Results: Although there was no statistical significant difference between both groups as regards endoscopic nasal examination posttreatment, patients of group B were statistically better as regards clinical and subjective parameters.Conclusion: We suggest that omalizumab has more superior effect than local steroids in controlling nasal symptoms in AFRS patients despite the same endoscopic scores post-treatment. More well-designed large prospective randomized controlled trials to determine the effects and optimal dosage and duration of omalizumab therapy in patients with AFRS will be necessary.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
di发布了新的文献求助10
1秒前
2秒前
2秒前
老登完成签到,获得积分20
2秒前
dorLi完成签到,获得积分10
3秒前
大模型的应助被一步一步0617采纳,获得10
3秒前
adasda发布了新的文献求助10
3秒前
3秒前
肥猫发布了新的文献求助10
3秒前
句号完成签到 ,获得积分10
4秒前
段棋晔发布了新的文献求助10
4秒前
兴奋彩虹完成签到,获得积分10
4秒前
4秒前
土豆泥拉拉完成签到,获得积分10
5秒前
淡然一笑完成签到,获得积分10
7秒前
xiejuan发布了新的文献求助10
7秒前
7秒前
8秒前
zhangxin完成签到 ,获得积分10
8秒前
三白发布了新的文献求助10
8秒前
RuiLi完成签到,获得积分10
9秒前
9秒前
飘逸晓蕾完成签到 ,获得积分20
9秒前
CodeCraft的应助被zyy采纳,获得10
10秒前
10秒前
苏11发布了新的文献求助30
10秒前
LuXiaoyu的应助被hua采纳,获得10
10秒前
南方完成签到,获得积分10
11秒前
suanqi512发布了新的文献求助10
11秒前
gala的夏天发布了新的文献求助10
11秒前
科目三的应助被哈哈哈哈采纳,获得10
11秒前
漂亮的沛萍完成签到,获得积分10
12秒前
jin完成签到,获得积分10
12秒前
12秒前
12秒前
12秒前
13秒前
上官富贵完成签到,获得积分10
13秒前
缓慢的橘子完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181379
求助须知:如何正确求助?哪些是违规求助? 9571317
关于积分的说明 21817457
捐赠科研通 7777820
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479523